1. ¹Pediatric Oncology Unit, Centre Léon-Bérard, Lyon, France
2. ²Cell Therapy Laboratory, Centre Léon-Bérard, Lyon, France
3. ³Anesthesia – Resuscitation Department, Centre Léon-Bérard, Lyon, France

Correspondence: Dr P Marec-Bérard, Pediatric Oncology Unit, Centre Léon-Bérard, 28 rue Laennec, Lyon 69373, France. E-mail: marec@lyon.fnclcc.fr

Received 6 December 2006; Revised 24 April 2007; Accepted 3 May 2007; Published online 2 July 2007.

Abstract

Collection of PBSC by leukapheresis requires one venous access (VA) for inflow and one for outflow. The use of implantable venous access devices (IVAD) has never been reported in this setting. We retrospectively analyzed the use of IVAD for performing apheresis. The study was conducted between January 2000 and June 2005 on 64 patients (41 children) requiring intensification for treatment of a solid tumor. Mean body weight was 26 kg (range 8–91 kg) for a median age of 8.5 years (range 0.7–66 years). A total of 121 aphereses were performed (mean 1.89 apheresis/patient). The second VA was in a cubital vein in 84 procedures and was a temporary central VA in 31. Mean duration of apheresis was 3 h (range 30–274 min). Mean flow rate was 41.3 ml/min (range 12–85 ml/min). Mean collection rate was 59.2% for CD34+ cells and 70% for mononuclear cells. The total number of CD34+ cells collected was 2.5 10⁶/kg per apheresis, and 5.9 10⁶/kg per patient. Several complications occurred: one catheter-related sepsis (0.86%), four catheter occlusions (3.47%) and eight hemodynamic instabilities related to extracorporeal volume. Weight <10 kg is a risk factor for complication (P=0.0006). IVAD are effective and safe for PBSC collection. Placement of a second central VA (requiring general anesthesia for children) could be avoided.